Article
Clinical Neurology
Simone Quintana, Marco Russo, Gian Camillo Manzoni, Paola Torelli
Summary: This observational study compares the efficacy, safety, and impact of anti-CGRP monoclonal antibodies on additional parameters such as disability in social, family, and work activities.
NEUROLOGICAL SCIENCES
(2022)
Review
Medicine, General & Internal
Lars Edvinsson
Summary: Migraine is a common neurovascular disorder, affecting over 15% of the global population. Women are three times more likely to suffer from migraine compared to men. The underlying mechanisms of migraine are still largely unknown, but molecules such as CGRP play a crucial role in its pathophysiology.
JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Clinical Neurology
Anna P. Andreou, Matteo Fuccaro, Bethany Hill, Madeleine Murphy, Valeria Caponnetto, Rachael Kilner, Giorgio Lambru
Summary: This study analyzed the long-term sustained effectiveness of erenumab in treating resistant chronic migraine. The findings revealed that only a minority of patients maintained good efficacy over a period of two years. However, erenumab can still provide relief in terms of reducing migraine load and related disability in some patients.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Clinical Neurology
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, Carmelina Maria Costa, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Valentina Favoni, Carlo Lovati, Davide Bertuzzo, Florindo D'Onofrio, Alberto Doretti, Paola Di Fiore, Cinzia Finocchi, Francesca Schiano Di Cola, Angelo Ranieri, Bruno Colombo, Francesco Bono, Maria Albanese, Sabina Cevoli, Piero Barbanti
Summary: This study found that in patients with chronic migraine, unilateral pain, a good response to triptans, and normal weight may be associated with a persistent positive response in the first 3 months of therapy with galcanezumab.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Simone de Vries Lentsch, Ingrid M. Garrelds, A. H. Jan Danser, Gisela M. Terwindt, Antoinette MaassenVanDenBrink
Summary: This study evaluated the serum levels of Calcitonin Gene-Related Peptide (CGRP)-like immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with erenumab, and examined their association with clinical treatment response. The results showed that lower levels of serum CGRP-LI 2-4 weeks after starting treatment with erenumab were associated with a higher reduction in migraine days after three months of treatment. This suggests that changes in CGRP levels shortly after starting erenumab are important for its clinical effect.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Food Science & Technology
Andreas A. A. Argyriou, Emmanouil V. V. Dermitzakis, Georgia Xiromerisiou, Michail Vikelis
Summary: This study aimed to evaluate the effectiveness of combining dual therapy with BTX and anti-CGRP MAbs in treatment-refractory CM patients. Retrospective review of medical files of 19 patients showed that dual therapy was effective and associated with significant clinical improvement in the majority of cases, with favorable safety and tolerability.
Article
Pharmacology & Pharmacy
Bianca Raffaelli, Maria Terhart, Mira Pauline Fitzek, Kristin Sophie Lange, Jasper Mecklenburg, Lucas Hendrik Overeem, Anke Siebert, Elisabeth Storch, Uwe Reuter
Summary: Discontinuation of treatment with CGRP(-receptor) monoclonal antibodies (mAb) does not affect free CGRP plasma concentrations, but leads to a significant decrease in total CGRP concentrations after three months. This study highlights the importance of understanding the mechanisms behind the increase in migraine frequency following mAb discontinuation.
Article
Clinical Neurology
Edoardo Caronna, Victor Jose Gallardo, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich
Summary: In real-life clinical practice, anti-CGRP monoclonal antibodies are effective in chronic migraine patients with medication overuse as well as those without it, leading to a reduction in headache frequency and acute medication use. The choice of different monoclonal antibodies does not affect the resolution of medication overuse, and patients with lower pain severity at baseline are more likely to stop overusing medications.
JOURNAL OF HEADACHE AND PAIN
(2021)
Review
Pharmacology & Pharmacy
Yao-Yao Chen, Xiao-Qian Ye, Tai-Chun Tang, Tian-Wei She, Min Chen, Hui Zheng
Summary: This study conducted an adjusted indirect comparison between CGRPmAbs and BoNT-A, finding similar effectiveness in the preventive treatment of chronic migraine. BoNT-A may be preferentially selected due to its cost-effectiveness. Further studies with direct comparison are needed to confirm these findings.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Food Science & Technology
Damiana Scuteri, Paolo Tonin, Pierluigi Nicotera, Marilu Vulnera, Giuseppina Cristina Altieri, Assunta Tarsitano, Giacinto Bagetta, Maria Tiziana Corasaniti
Summary: The combination therapy of anti-CGRP mAbs and onabotulinumtoxinA in chronic migraine shows promising results, with up to 58.8% of patients experiencing a reduction of >= 50% in monthly headache days. Compared to anti-CGRP mAbs and onabotulinumtoxinA alone, the combination therapy leads to a greater decrease in headache days, suggesting its potential efficacy. However, more well-designed studies are needed to further confirm the effectiveness and safety of this combination therapy. PROSPERO registration: CRD42022313640.
Article
Clinical Neurology
Fabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, Cinzia Aurilia, Gabriella Egeo, Carlo Lovati, Valentina Favoni, Armando Perrotta, Ilaria Maestrini, Renata Rao, Luigi d'Onofrio, Cinzia Finocchi, Marco Aguggia, Francesco Bono, Angelo Ranieri, Maria Albanese, Vittorio Di Piero, Sabina Cevoli, Claudia Altamura, Piero Barbanti
Summary: This study evaluated the 1-year effectiveness and tolerability of galcanezumab in real-life treatment of high-frequency episodic and chronic migraine. The results showed that a majority of patients experienced a significant reduction in monthly migraine days for at least 9 months. Triptan response, lower body mass index, and an early reduction in migraine days were identified as predictive factors for a persistent response.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Medicine, General & Internal
Michail Vikelis, Emmanouil V. Dermitzakis, Georgia Xiromerisiou, Dimitrios Rallis, Panagiotis Soldatos, Pantelis Litsardopoulos, Dimitrios Rikos, Andreas A. Argyriou
Summary: This post hoc analysis aimed to evaluate the efficacy of fremanezumab in difficult-to-treat chronic migraine patients with and without psychiatric comorbidities. The results showed that fremanezumab is effective in reducing headache days, improving disability and quality of life, and reducing the severity of psychiatric comorbidities.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Clinical Neurology
Bianca Raffaelli, Maria Terhart, Lucas Hendrik Overeem, Jasper Mecklenburg, Lars Neeb, Maureen Steinicke, Uwe Reuter
Summary: The cessation of CGRP(-receptor) antibodies migraine prophylaxis led to a significant increase in migraine frequency and acute medication intake over time. However, by weeks 13-16, the monthly migraine days were not significantly different from baseline values.
Article
Clinical Neurology
Fabrizio Vernieri, Nicoletta Brunelli, Simona Guerzoni, Luigi Francesco Iannone, Carlo Baraldi, Renata Rao, Francesca Schiano di Cola, Raffaele Ornello, Sabina Cevoli, Carlo Lovati, Maria Albanese, Armando Perrotta, Ilaria Cetta, Sergio Soeren Rossi, Valentina Taranta, Massimo Filippi, Pierangelo Geppetti, Simona Sacco, Claudia Altamura
Summary: This study evaluated the outcome of migraine patients treated with monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (anti-CGRP) or its receptor (anti-CGRPr). The effectiveness of these mAbs did not differ between the first and second year of treatment. The results suggest that anti-CGRP/CGRPr mAbs are effective in both years.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Marcello Silvestro, Alessandro Tessitore, Ilaria Orologio, Rosa De Micco, Lorenzo Tartaglione, Francesca Trojsi, Gioacchino Tedeschi, Antonio Russo
Summary: This study reports the clinical experience of using galcanezumab for migraine treatment in a real-world setting in Italy. The results show that galcanezumab significantly reduces the frequency, intensity, and duration of headache attacks, and improves migraine-related disability, impact, and quality of life, as well as comorbid depressive or anxious symptoms and pain catastrophizing.
JOURNAL OF HEADACHE AND PAIN
(2022)
